Physician profile
Jon Failla
NPI 1326474685
$73,697.25
in general payments reported to CMS, 2019-2025
21 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,534 · 2022: $1,395 · 2023: $2,063 · 2024: $7,850 · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $11K · Food and Beverage: $8,608 · Travel and Lodging: $4,146 · Education: $6.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,440.00 |
| Consulting Fee | $10,567.50 |
| Food and Beverage | $8,607.94 |
| Travel and Lodging | $4,146.05 |
| Education | $6.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $35,346.24 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $20,482.60 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $12,617.40 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,385.08 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,182.46 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $943.01 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $444.53 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| E.R. Squibb & Sons, L.L.C. | $343.78 | 2024-2025 | Cobenfy |
| Bioxcel Therapeutics, INC. | $222.92 | 2023 | Igalmi |
| Corium, LLC | $125.00 | 2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| La Jolla Pharmaceutical Company | $121.83 | 2024 | Xacduro |
| Vanda Pharmaceuticals INC. | $87.58 | 2022 | |
| Indivior INC. | $61.35 | 2023 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $45.84 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $42.48 | 2021-2022 | |
| Eisai INC. | $32.18 | 2021 | |
| Lundbeck LLC | $30.23 | 2021 | |
| Avanir Pharmaceuticals, INC. | $24.17 | 2021 | |
| Almatica Pharma LLC | $17.57 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Failla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.